Pharmaceutical

Actimed plans trials to treat muscle wasting syndrome in cancer patients

The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.

Jul 13, 2023 - 20:00
Actimed plans trials to treat muscle wasting syndrome in cancer patients
The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.
Read the original article

Tags:

Previous Article

FDA greenlights first over-the-counter birth control pill

Next Article

NVIDIA invests $50m in AI-enabled drug discovery

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Bluebird submits sickle cell gene therapy to FDA for approval

STAT+: Bluebird submits sickle cell gene therapy to FDA...

Apr 25, 2023

STAT+: Pharmalittle: FDA approves BioMarin gene therapy for hemophilia A; former Pfizer worker charged with insider trading

STAT+: Pharmalittle: FDA approves BioMarin gene therapy...

Jun 30, 2023

Cristália signs licensing deal for Formosa’s APP13007

Cristália signs licensing deal for Formosa’s APP13007

Jan 29, 2024